Hemoglobinopathy Drugs Market Provides Information on Historical Growth, Analysis, Opportunities and Forecast To 2029
Hemoglobinopathy Drugs Market is anticipated to grow at a significant CAGR during the forecast period. Hemoglobinopathy is a group of hereditary blood disorders involving an abnormality in the structure of haemoglobin. These disorders include both sickle cell disease (SCD) and thalassemia. Common symptoms of the condition include severe pain, shortness of breath, enlarged spleen, and growth problems in children. Other types of hemoglobinopathies linked to the structural haemoglobin variants are HbS, HbE, and HbC.
The major factor that is expected
to boost the global hemoglobinopathy drugs market includes the increasing
incidence and prevalence of sickle cell disease, which will propel the growth
of the global hemoglobinopathy treatment drugs market over the forecast period.
For instance, according to the data published in Centers for Disease Control
and Prevention in October 2019, SCD affects around 100,000 Americans every
year. Moreover, as per the same source, around 1 in 13 African-American babies
are born with sickle cell trait.
The global hemoglobinopathy drugs market analysis includes
some of the key market players such as GlycoMimetics Inc., Pfizer Inc., Anthera
Pharmaceuticals Inc., Eli Lilly and Company, and Mast Therapeutics, among
others. To maintain a strong position in the market, these market players are
adopting various strategic moves, such as product launches, partnerships,
collaborations, and mergers and acquisitions. For instance, in July 2018, the
European Medicines Agency’s Committee for Medicinal Products for Human Use
granted the bluebird bio LentiGlobin therapy for use in the treatment of
hemoglobinopathy disorders among patients.
To Request a Sample of our Report on Hemoglobinopathy Drugs
Market: https://www.omrglobal.com/request-sample/hemoglobinopathy-drugs-market
•
The market number available for – 2022-2030
•
Base year- 2022
•
Forecast period- 2023-2030
•
Segment Covered
•
Regions Covered- Globally
Competitive
Landscape: GlycoMimetics
Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, and
Mast Therapeutics, among others.
A full Report of Hemoglobinopathy Drugs Market is Available @ https://www.omrglobal.com/industry-reports/hemoglobinopathy-drugs-market
Hemoglobinopathy Drugs Market by Segment
By Type
• Hydroxyurea
• Glutamine
• Zynteglo
• Other
By Distribution Channel
• Retail
Pharmacy
• Hospital
Pharmacy
• Online
Pharmacy
Hemoglobinopathy Drugs Market by Region
· United
States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest
of Europe
Asia-Pacific
· India
· China
· Japan
· South
Korea
· Rest
of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More Customized Data,
Request for Report Customization @ https://www.omrglobal.com/report-customization/hemoglobinopathy-drugs-market
About Orion Market Research
Orion Market Research (OMR) is a market research and
consulting company known for its crisp and concise reports. The company is
equipped with an experienced team of analysts and consultants. OMR offers
quality syndicated research reports, customized research reports, consulting
and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and
Consulting Services through another subsidiary Encanto Technologies.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment